Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies of proposals published on 1 March 2023 by the Association of the British Pharmaceutical Industry for an Investment Facility, including the potential impact of those proposals on (a) clinical research capacity, (b) genomics capacity, (c) real world data capability and (d) equitable medicines use.

The Department has seen the proposals published on 1 March; they will be considered as part of formal negotiations for a future voluntary scheme.

The Government is open to ideas about how a successor to the voluntary scheme for branded medicines pricing and access should operate from 2024 onwards and will work with industry to agree a mutually beneficial successor that supports better patient outcomes, ensures the sustainability of National Health Service spend on branded medicines, and enables a strong life sciences industry.